SLC5A2 and type 2 diabetes mellitus: To the best of our knowledge, this is the first study to show that the use of SGLT2 inhibitors in patients with CVD and T2DM does not interfere with the improvement in outcomes regarding skeletal muscle function in outpatient CR.